Pluri PLUR
NASDAQ PLUR
$1.37 +0.10 (+7.87%)
At close: Sep 9, 2026 · 4:00 PM EDT

Pluri (PLUR) Non Operating Interest Expenses (2010 - 2025)

Pluri's (PLUR) quarterly Non Operating Interest Expenses came in at $231000.0 in Q4 2025, up 9.48% year-over-year from $211000.0 in Q4 2024, and up 0.87% quarter-over-quarter from $229000.0 in Q3 2025.

Analysis

Pluri (PLUR) Non Operating Interest Expenses (2010 - 2025) Analysis & Trends

Pluri (PLUR) has reported Non Operating Interest Expenses for 8 consecutive years, with $231000.0 the latest figure, recorded in Q4 2025.

  • On a quarterly basis, Non Operating Interest Expenses rose 9.48% year-over-year to $231000.0 in Q4 2025; TTM through Dec 2025 was $905000.0, a 4.75% increase from a year earlier, with the FY2025 full-year figure at $873000.0, up 0.81% from the prior year.
  • Non Operating Interest Expenses was $231000.0 for Q4 2025 at Pluri, up from $229000.0 in the prior quarter.
  • Over five years, Non Operating Interest Expenses peaked at $233000.0 in Q2 2025 and troughed at $194000.0 in Q3 2022.
  • A 4-year average of $217285.7 and a median of $217000.0 in 2023 frame the typical range for Non Operating Interest Expenses.
  • Across the five-year window, Non Operating Interest Expenses grew 10.31% in 2023 and fell 2.75% in 2025, its largest moves.
  • Over 4 years, Non Operating Interest Expenses stood at $212000.0 in 2022, then gained by 1.89% to $216000.0 in 2023, then declined by 2.31% to $211000.0 in 2024, then grew by 9.48% to $231000.0 in 2025.
  • The last three Non Operating Interest Expenses figures came in at $231000.0 (Q4 2025), $229000.0 (Q3 2025), and $233000.0 (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Krystal Biotech 10.27 Bn 9.43 Bn 112.79 Mn -
2 CRISPR Therapeutics AG 5.17 Bn 5.17 Bn - -
3 Iovance Biotherapeutics 3.79 Bn 3.49 Bn 55.72 Mn 4.00 Bn
4 Legend Biotech 3.68 Bn 2.71 Bn 251.50 Mn -5.80 Mn
5 uniQure 3.05 Bn 3.05 Bn 5.49 Mn 14.37 Mn
6 Beam Therapeutics 2.65 Bn 2.65 Bn - -
7 Precigen 2.44 Bn 2.44 Bn 52.17 Mn 2.95 Mn
8 Sarepta Therapeutics 2.33 Bn 1.53 Bn 251.87 Mn -
9 Vericel 1.99 Bn 1.83 Bn 56.40 Mn 160,000.00
10 Pluri 11.95 Mn -536,034.04 86,000.00 231,000.00
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 231,000.00
Sep 30, 2025 229,000.00
Jun 30, 2025 233,000.00
Mar 31, 2025 212,000.00
Dec 31, 2024 211,000.00
Sep 30, 2024 217,000.00
Jun 30, 2024 218,000.00
Mar 31, 2024 218,000.00
Dec 31, 2023 216,000.00
Sep 30, 2023 214,000.00
Jun 30, 2023 220,000.00
Mar 31, 2023 217,000.00
Dec 31, 2022 212,000.00
Sep 30, 2022 194,000.00
Sep 30, 2013 105,000.00
Jun 30, 2013 226,000.00
Mar 31, 2013 253,000.00
Dec 31, 2012 394.00
Sep 30, 2012 195,000.00
Jun 30, 2012 -164,000.00